Publications:

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.

Ebiomedicine

Hoyer, K K; Hablesreiter, R R; Inoue, Y Y; Yoshida, K K; Briest, F F; Christen, F F; Kakiuchi, N N; Yoshizato, T T; Shiozawa, Y Y; Shiraishi, Y Y; Striefler, J K JK; Bischoff, S S; Lohneis, P P; Putter, H H; Blau, O O; Keilholz, U U; Bullinger, L L; Pelzer, U U; Hummel, M M; Riess, H H; Ogawa, S S; Sinn, M M; Damm, F F

Publication Date: 2021-04

Variant appearance in text: TP53: 705delC

PubMed Link: 33862582

Variant Present in the following documents:

• mmc3.xlsx, sheet 2

View BVdb publication page

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Bmc Cancer

Lupini, Laura L; Bassi, Cristian C; Mlcochova, Jitka J; Musa, Gentian G; Russo, Marta M; Vychytilova-Faltejskova, Petra P; Svoboda, Marek M; Sabbioni, Silvia S; Nemecek, Radim R; Slaby, Ondrej O; Negrini, Massimo M

Publication Date: 2015-10-27

Variant appearance in text: TP53: 705delC

PubMed Link: 26508446

Variant Present in the following documents:

• 12885_2015_1752_MOESM3_ESM.xlsx, sheet 1

View BVdb publication page